Sadip Pant, MD
Interventional Cardiology · Louisville, KYNPI 1205124724
Payments from drug & device makers
Across 573 payments — averaging $78.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Inari Medical, Inc.$9K
- Edwards Lifesciences$7K
- Stryker$5K
- Boston Scientific$3K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $6K from 32 others
What the payments were for
- Consulting fees$10,02023%
- Speaking & faculty fees$10,27524%
- Travel & lodging$9,27422%
- Food & beverage$13,34431%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 64 | $12,360 |
| Inari Medical, Inc. | 23 | $9,234 |
| Edwards Lifesciences | 25 | $7,327 |
| Stryker | 9 | $5,199 |
| Boston Scientific | 39 | $2,987 |
| E.r. Squibb & Sons, L.L.C. | 71 | $1,506 |
| Novartis | 114 | $1,284 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 38 | $735 |
| Amgen | 32 | $547 |
| Pfizer | 26 | $463 |
| AstraZeneca | 12 | $400 |
| Johnson & Johnson | 18 | $329 |
| Abbott | 4 | $240 |
| Merck | 12 | $233 |
| Philips North America LLC | 6 | $222 |
| Novo Nordisk | 8 | $201 |
| Getinge USA Sales, LLC | 8 | $199 |
| Alnylam Pharmaceuticals Inc. | 8 | $170 |
| Esperion Therapeutics, Inc. | 7 | $127 |
| Penumbra, Inc. | 1 | $115 |
| Angiodynamics, Inc. | 2 | $96 |
| Terumo Medical Corporation | 2 | $94 |
| Gilead | 4 | $92 |
| Scpharmaceuticals Inc. | 5 | $90 |
| Kowa Pharmaceuticals America, Inc. | 6 | $90 |
| Boehringer Ingelheim | 4 | $89 |
| Bayer | 3 | $76 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $63 |
| Biotronik Inc. | 2 | $61 |
| Baxter Healthcare | 1 | $59 |
| EKOS Corporation | 2 | $55 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Amarin Pharma, Inc. | 3 | $50 |
| Abiomed | 3 | $50 |
| Shockwave Medical, Inc | 2 | $46 |
| Actelion Pharmaceuticals US, Inc. | 1 | $39 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$13,774
- CT THROMBECTOMY SYSTEM KIT$13,774
- CoreValve Evolut$7,520
- Edwards SAPIEN 3 Transcatheter Heart Valve$5,250
- WATCHMAN Access System$1,641
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,590
- COREVALVE EVOLUT R$1,337
- TEZSPIRE$125
- Micra$123
- Confirm Rx$117
- Indigo$115
- LifeVest$110
How this compares
$45,028 in reported general payments places this provider in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 318 | $291,452 |
| EntrestoSacubitril/Valsartan | 18 | $25,046 |
| FarxigaDapagliflozin Propanediol | 31 | $21,239 |
| XareltoRivaroxaban | 27 | $20,449 |
| Repatha SureclickEvolocumab | 30 | $17,232 |
| Metoprolol Succinate | 135 | $2,104 |
| ClopidogrelClopidogrel Bisulfate | 117 | $1,692 |
| Ezetimibe | 30 | $1,472 |
| Rosuvastatin Calcium | 33 | $1,204 |
| Furosemide | 168 | $931 |
| Atorvastatin Calcium | 114 | $898 |
| Losartan Potassium | 75 | $886 |
| Bumetanide | 11 | $820 |
| Metoprolol Tartrate | 129 | $630 |
| Flecainide Acetate | 12 | $609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $463 | $291,452318 claims |
| NovartisEntresto | $1,284 | $25,04618 claims |
| AstraZenecaFarxiga | $400 | $21,23931 claims |
| Johnson & JohnsonXarelto | $329 | $20,44927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Louisville
- Thomas TuLouisville$1.4M
- Naresh SolankhiLouisville$545K
- Sreedevi GondiLouisville$535K
- Daniel StewartLouisville$290K
- Daniel RothschildLouisville$203K
- Ravi SharmaLouisville$109K
- Christopher SemderLouisville$103K
- Abdullahi OseniLouisville$97K
- Michael FlahertyLouisville$87K
- Prafull RahejaLouisville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.